• Cantor Fitzgerald reaffirmed an "Overweight" rating for CVRx, Inc. (NASDAQ: CVRX), with the stock price at $10.55.
• The American Medical Association (AMA) approved new CPT Category I codes for CVRx's Barostim therapy, effective January 1, 2026.
• CVRX stock price has risen to $10.91, reflecting a 14.96% increase, amidst active trading following the AMA's approval.

On October 21, 2024, Cantor Fitzgerald maintained its "Overweight" rating for CVRx, Inc. (NASDAQ: CVRX), a company specializing in medical devices. The stock was held at a price of $10.55. CVRx focuses on innovative therapies for heart failure, with its flagship product being Barostim, a baroreflex activation therapy.

Recently, CVRx announced that the American Medical Association (AMA) approved new CPT Category I codes for Barostim. This approval is significant as it acknowledges the therapy's growing use and positive clinical outcomes. The new codes, effective January 1, 2026, will likely improve reimbursement processes for healthcare providers, broadening patient access to Barostim.

The stock price of CVRX has seen a notable increase, currently trading at $10.91, up by 14.96% or $1.42. This rise reflects investor optimism following the AMA's approval. The stock has fluctuated today between $9.65 and $11.03, indicating active trading interest.

CVRx's market capitalization is approximately $237.68 million, with a trading volume of 583,553 shares. Over the past year, the stock has experienced a high of $33.14 and a low of $6.40. This volatility highlights the market's response to the company's developments and potential growth prospects.